📑 Extensive Product Profile: Understanding Carbolieva 150 Injection

Carbolieva 150 Injection contains Carboplatin (150mg), an advanced, second-generation platinum-based cytotoxic chemotherapy agent (alkylating-like substance). Manufactured to rigorous international quality benchmarks, it is extensively deployed by global oncologists as a foundational component in single-agent and combination systemic chemotherapy regimens to manage diverse, advanced, and mutation-specific malignancies.

1. Clinical Indications & Usage

Carbolieva 150 Injection is an intravenous targeted systemic chemotherapy globally indicated for:

• Advanced Ovarian Carcinoma:

• First-Line Therapy: Indicated for the treatment of advanced epithelial ovarian carcinoma in combination with other established chemotherapeutic agents (e.g., paclitaxel).

• Palliative Therapy: Deployed as a single agent for the palliative treatment of patients with recurrent epithelial ovarian carcinoma who have previously received chemotherapy.

• Small Cell and Non-Small Cell Lung Cancer (SCLC/NSCLC): Widely utilized internationally in combination therapy regimens for the management of locally advanced or metastatic bronchogenic carcinomas.

• Other Malignancies: Frequently incorporated into institutional clinical protocols for head and neck cancers, cervical carcinomas, and bladder malignancies where platinum-based cytotoxic intervention is indicated.

2. Mechanism of Action: How Carbolieva Works

Carbolieva utilizes a highly effective intracellular alkylation pathway to selectively arrest the cell division cycle of highly proliferative malignant cells:

• Intracellular Activation: Following intravenous administration, Carboplatin diffuses across cell membranes. It undergoes a slow aquation process where its leaves-group (cyclobutane-dicarboxylate) is displaced by water molecules, forming an active platinum intermediate.

• DNA Cross-Linking: The activated platinum complex binds preferentially to the nucleophilic sites on DNA, creating intrastrand and interstrand cross-links. These cross-links alter the structural integrity of the DNA double helix.

• Inhibition of Replication & Apoptosis: The physical deformation of DNA blocks transcription and halts DNA replication enzymes. In rapidly dividing cancer cells, these irreversible structural lesions trigger cellular stress pathways, forcing the heavily damaged cell into programmed cell death (apoptosis).

3. Administration and Dosing Guide

• Administration Route: Carbolieva 150 Injection is strictly for Intravenous (IV) Infusion. It must be diluted with appropriate sterile vehicles (e.g., 5% Dextrose or 0.9% Sodium Chloride) prior to administration and must never be given via rapid bolus injection.

• Dosing Calculation (Calvert Formula): Unlike many cytotoxic agents dosed by Body Surface Area the clinical dosage of Carboplatin is frequently calculated using the Calvert Formula to target a specific Area Under the Curve incorporating the patient's renal function (Glomerular Filtration Rate 

• Standard Schedule: Typically administered as a single intravenous infusion over 15 to 60 minutes once every 4 weeks, allowing for hematological recovery between cycles. Dose modifications or delays are managed directly by the supervising oncologist based on nadir blood counts.

⚠️ Safety, Side Effects, and Monitoring

Carbolieva 150 Injection is a highly potent antineoplastic agent requiring strict clinical oversight:

• Bone Marrow Suppression (Myelosuppression): The primary dose-limiting toxicity is severe bone marrow suppression. Anemia, leukopenia, neutropenia, and thrombocytopenia occur regularly. Baseline and weekly Complete Blood Counts (CBC) are mandatory to track platelet and white blood cell nadirs.

• Nephrotoxicity & Electrolyte Depletion: While less nephrotoxic than cisplatin, it can cause renal impairment and significant electrolyte wasting (loss of magnesium, potassium, and calcium). Regular renal function testing and electrolyte monitoring are required.

• Anaphylactic Reactions: Hypersensitivity reactions, including rash, urticaria, erythema, and rare bronchospasms, can occur within minutes of injection. Epinephrine and supportive care equipment must be readily available during administration.

• Common Side Effects: Nausea, vomiting, severe fatigue, peripheral neuropathy (numbness/tingling), temporary hair loss (alopecia), and altered taste perception.

📦 Storage and Handling Specifications

• Storage Framework: Store intact Carbolieva 150mg vials between 15°C to 25°C (59°F to 77°F) in a dry, dark, climate-controlled warehouse corridor.

• Environmental Safeguards: Keep the vials sealed inside their original manufacturer protective cartons. Protect strictly from direct ambient UV light exposure and do not freeze. Keep out of reach of children and domestic animals.

• Cytotoxic Handling: Disposal of needles, syringes, unused solution, and material used for reconstitution must follow strict institutional biohazard protocols for cytotoxic drugs.

📄 Regulatory and Compliance Documentation

PRIMECARE IMPEX simplifies international border clearance and institutional sourcing workflows by providing a comprehensive, audit-ready document pack with every consignment:

• Authentic Certificate of Analysis (COA) c

• Verified Batch Origin Ledger and commercial export documentation.

• GMP compliant manufacturing credentials.

💡 Why Choose PRIMECARE IMPEX?

Sourcing your institutional pharmaceuticals through PRIMECARE IMPEX guarantees a highly secure, verified supply chain setup:

• Full Traceability

• Regulatory Alignment

• Secure Bulk Supply

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India.

• 🌐 Corporate Website: www.medicineexporterfromindia.com

• 📧 Commercial Email: exports@ernestpharmaceuticals.com

• 📦 Business Type: Exporter | Bulk Supplier | Distributor

• 📲 Direct WhatsApp Line: +91 9673008130

• 🔗 Instant Chat Access: https://wa.me/919673008130